## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

**SCHEDULE 13G** 

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)\*

CRISPR Therapeutics AG
(Name of Issuer)
Common stock
(Title of Class of Securities)
H17182108
(CUSIP Number)
December 31, 2021
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
⊠ Rule 13d-1(b)
□ Rule 13d-1(c)
☐ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

-						
	NAMESO	E DE	DODTING DEDSONS			
1.	NAMES OF REPORTING PERSONS  ARK Investment Management LLC					
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			PPROPRIATE BOX IF A MEMBER OF A GROUP			
				(a)□ (b)□		
3.	SEC USE ONLY					
CITIZENSHIP OR PLACE OF ORGANIZATION		OR PLACE OF ORGANIZATION				
4.	Delaware, United States					
	1		SOLE VOTING POWER			
		<b>5.</b>	8,157,143			
NUN	NUMBER OF		SHARED VOTING POWER			
SHARES BENEFICIALLY		6.	702,401			
F	NED BY EACH		SOLE DISPOSITIVE POWER			
	ORTING SON WITH	7.	9,087,868			
			SHARED DISPOSITIVE POWER			
		8.	0			
	AGGREGA	ATE A	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
9.	9,087,868					
4.0	CHECK IF	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
10.						
44	PERCENT	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11.	11.88%					
TYPE OF REPORTING PERSON						
<b>12.</b>	IA					

13G

Page 2 of 5 Pages

CUSIP No. H17182108

CUSIP No. H17182108	13G	Page 3 of 5 Pages				
Item 1(a) Name of issuer:						
CRISPR Therapeutics AG						
Item 1(b) Address of issuer's principal executive of	ifices:					
Baarerstrasse 14 Zug V8 CH-6300						
Item 2(a) Name of person filing:						
ARK Investment Management LLC						
Item 2(b) Address or principal business office or, it	f none, residence:					
ARK Investment Management LLC 3 East 28th Street, 7th Floor New York, NY 10016						
Item 2(c) Citizenship:						
Delaware, United States						
Item 2(d) Title of class of securities:						
Common stock						
Item 2(e) CUSIP No.:						
H17182108						
Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:						
(a) $\square$ Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);						
b) $\square$ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);						
(c) $\square$ Insurance company as defined in section 3(a)(1	c) $\square$ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);					
d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);						
e) ⊠ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);						
f) $\square$ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);						
(g) $\square$ A parent holding company or control person in	accordance with § 240.13d-1(b)(1)(ii)(G);					
(h) $\square$ A savings associations as defined in Section 3(	o) of the Federal Deposit Insurance Act (12 U.S.C.	1813);				

CUSIP No. H17182	108	13G	Page 4 of 5 Pages					
(i) ☐ A church plan th U.S.C. 80a-3);	aat is excluded from the definitio	on of an investment company under section 3(c)(14	) of the Investment Company Act of 1940 (15					
(j) □ A non-U.S. insti	tution in accordance with § 240.	13d-1(b)(1)(ii)(J);						
(k) ☐ Group, in accortype of institution:	dance with § 240.13d-1(b)(1)(ii) —	(K). If filing as a non-U.S. institution in accordance	ee with § 240.13d-1(b)(1)(ii)(J), please specify the					
Item 4. Ownership								
(a) Amount ben	eficially owned:							
9,087,868								
(b) Percent of cl	ass:							
11.88%	11.88%							
(c) Number of s	Number of shares as to which such person has:							
(i) Sole pow	(i) Sole power to vote or to direct the vote: 8,157,143							
(ii) Shared po	(ii) Shared power to vote or to direct the vote: 702,401							
(iii) Sole pow	ver to dispose or to direct the dis	position of: 9,087,868						
(iv) Shared p	ower to dispose or to direct the c	disposition of: 0						
Item 5. Ownership of	f 5 Percent or Less of a Class.							
Not applicable.								
Item 6. Ownership of	f More than 5 Percent on Beha	lf of Another Person.						
Not applicable.								
Item 7. Identification Control Person.	and Classification of the Subs	sidiary Which Acquired the Security Being Repo	orted on by the Parent Holding Company or					
Not applicable.								
Item 8. Identification	and Classification of Member	rs of the Group.						
Not applicable.								
Item 9. Notice of Diss	solution of Group.							
Not applicable.								
		_						

CUSIP No. H17182108	13G	Page 5 of 5 Pages
---------------------	-----	-------------------

## Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

## **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The reporting persons agree that this statement is filed on behalf of each of them.

Dated: February 9, 2022

## **ARK Investment Management LLC**

By: /s/ Kellen Carter

Name: Kellen Carter

Title: Chief Compliance Officer